#
# List of treatments for testing.  Each line is the following format:
#
# Gene\tVariant\tTumorType\tTreatments\tLevel
#

# Test KIT
KIT	N505I	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib;
KIT	N505I	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib;
KIT	N505I	Melanoma	2A: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
KIT	N505I	Colorectal Cancer	2B: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
KIT	N505I	Thymic Tumor	2A: Sunitinib; 2A: Sorafenib; 2B: Imatinib; 2B: Regorafenib;
KIT	N505L	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib;
KIT	N505L	Melanoma	2A: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
KIT	N505L	Colorectal Cancer	2B: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
KIT	N505L	Thymic Tumor	2A: Sunitinib; 2A: Sorafenib; 2B: Imatinib; 2B: Regorafenib;
KIT	M541L	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib;
KIT	M541L	Melanoma	2A: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
KIT	M541L	Colorectal Cancer	2B: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
KIT	M541L	Thymic Tumor	2A: Sunitinib; 2A: Sorafenib; 2B: Imatinib; 2B: Regorafenib;
KIT	M541C	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib;
KIT	M541C	Melanoma	2A: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
KIT	M541C	Colorectal Cancer	2B: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
KIT	M541C	Thymic Tumor	2A: Sunitinib; 2A: Sorafenib; 2B: Imatinib; 2B: Regorafenib;
KIT	Y553N	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib;
KIT	Y553N	Melanoma	2A: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
KIT	Y553N	Colorectal Cancer	2B: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
KIT	Y553N	Thymic Tumor	2A: Sunitinib; 2A: Sorafenib; 2B: Imatinib; 2B: Regorafenib;
KIT	Y553C	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib;
KIT	Y553C	Melanoma	2A: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
KIT	Y553C	Colorectal Cancer	2B: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
KIT	Y553C	Thymic Tumor	2A: Sunitinib; 2A: Sorafenib; 2B: Imatinib; 2B: Regorafenib;
#KIT	R643W	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib;
#KIT	R643W	Melanoma	2A: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
#KIT	R643W	Colorectal Cancer	2B: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
#KIT	R643W	Thymic Tumor	2A: Sunitinib; 2A: Sorafenib; 2B: Imatinib; 2B: Regorafenib;
KIT	D737N	Gastrointestinal Stromal Tumor
KIT	D737N	Melanoma
KIT	D737N	Colorectal Cancer
KIT	D737N	Thymic Tumor
KIT	C809G	Gastrointestinal Stromal Tumor	1: Regorafenib; 2A: Sorafenib; R2: Imatinib; R2: Sunitinib;
KIT	C809G	Melanoma	2A: Imatinib; 2B: Regorafenib; 2B: Sorafenib;
KIT	C809G	Colorectal Cancer	2B: Regorafenib; 2B: Sorafenib;
KIT	C809G	Thymic Tumor	2A: Sunitinib; 2A: Sorafenib; 2B: Regorafenib;
KIT	K642E	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib;
KIT	K642E	Melanoma	2A: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
KIT	K642E	Colorectal Cancer	2B: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
KIT	K642E	Thymic Tumor	2A: Sunitinib; 2A: Sorafenib; 2B: Imatinib; 2B: Regorafenib;
KIT	K642G	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib;
KIT	K642G	Melanoma	2A: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
KIT	K642G	Colorectal Cancer	2B: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
KIT	K642G	Thymic Tumor	2A: Sunitinib; 2A: Sorafenib; 2B: Imatinib; 2B: Regorafenib;
KIT	V654A	Gastrointestinal Stromal Tumor	1: Sunitinib; 1: Regorafenib; R2: Imatinib;
KIT	V654A	Melanoma	2A: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
KIT	V654A	Colorectal Cancer	2B: Sunitinib; 2B: Regorafenib;
KIT	V654A	Thymic Tumor	2A: Sunitinib; 2A: Sorafenib; 2B: Regorafenib;
KIT	V654G	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib;
KIT	V654G	Melanoma	2A: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
KIT	V654G	Colorectal Cancer	2B: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
KIT	V654G	Thymic Tumor	2A: Sunitinib; 2A: Sorafenib; 2B: Imatinib; 2B: Regorafenib;
KIT	T670I	Gastrointestinal Stromal Tumor	1: Sunitinib; 1: Regorafenib; R2: Imatinib;
KIT	T670I	Melanoma	2A: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
KIT	T670I	Colorectal Cancer	2B: Sunitinib; 2B: Regorafenib;
KIT	T670I	Thymic Tumor	2A: Sunitinib; 2A: Sorafenib; 2B: Regorafenib;
#KIT	T670C	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib;
#KIT	T670C	Melanoma	2A: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
#KIT	T670C	Colorectal Cancer	2B: Imatinib; 2B: Sunitinib; 2B: Regorafenib;
#KIT	T670C	Thymic Tumor	2A: Sunitinib; 2A: Sorafenib; 2B: Imatinib; 2B: Regorafenib;
KIT	D816A	Gastrointestinal Stromal Tumor	3B: Avapritinib;
KIT	D816A	Melanoma	2A: Imatinib; 3B: Avapritinib;
KIT	D816A	Colorectal Cancer	3B: Avapritinib;
KIT	D816A	Mastocytosis	3A: Avapritinib;
KIT	D816A	Thymic Tumor	2A: Sunitinib; 2A: Sorafenib; 3B: Avapritinib;
MTOR	L2427Q	Renal Clear Cell Carcinoma	3A: Temsirolimus;
PDGFRA	D842I	GIST	2A: Imatinib;
PDGFRA	D842I	Thymic Tumor	2B: Imatinib;
PDGFRA	D842V	GIST	R1: Imatinib; 2A: Dasatinib;
PDGFRA	D842V	Thymic Tumor	2B: Dasatinib; 2B: Imatinib;

#Test Heme
FLT3	Internal Tandem Duplication	AML	1: Gilteritinib; 1: Midostaurin+Intensive chemotherapy; 3A: Crenolanib; 3A: Entospletinib; 3A: High dose daunorubicin; 3A: Quizartinib; 3A: Sorafenib;
FLT3	Internal Tandem Duplication	APLPMLRARA	1: Gilteritinib; 1: Midostaurin+Intensive chemotherapy; 3A: Crenolanib; 3A: Entospletinib; 3A: High dose daunorubicin; 3A: Quizartinib; 3A: Sorafenib;
FLT3	Internal Tandem Duplication	Colorectal Cancer	3B: Sorafenib;
SF3B1	K700E	AML	4: H3B-8800;
SF3B1	K700E	AMLNOS	4: H3B-8800;
SF3B1	K700E	APLPMLRARA	4: H3B-8800;
SF3B1	K700E	Colorectal Cancer
DNMT3A	P904L	AML	3A: High dose daunorubicin;
DNMT3A	P904L	APLPMLRARA	3A: High dose daunorubicin;
DNMT3A	P904L	CMML
DNMT3A	P904L	Colorectal Cancer
ABL1	BCR-ABL1 Fusion	BLL	1: Dasatinib; 1: Imatinib; 1: Ponatinib; 2A: Bosutinib; 2A: MOpAD regimen; 2A: Nilotinib;
ABL1	BCR-ABL1 Fusion	BLLNOS	1: Dasatinib; 1: Imatinib; 1: Ponatinib; 2A: Bosutinib; 2A: MOpAD regimen; 2A: Nilotinib;
ABL1	BCR-ABL1 Fusion	BLLBCRABL1	1: Dasatinib; 1: Imatinib; 1: Ponatinib; 2A: Bosutinib; 2A: MOpAD regimen; 2A: Nilotinib;
ABL1	BCR-ABL1 Fusion	Colorectal Cancer	2B: Dasatinib; 2B: Imatinib; 2B: Nilotinib;
ABL1	E255K	CML	2A: Bosutinib; 2A: Dasatinib;
ABL1	E255K	CMLBCRABL1	2A: Bosutinib; 2A: Dasatinib;
ABL1	E255K	AML
ABL1	E255K	Colorectal Cacner
KMT2A	KMT2A-MLLT3 Fusion	AML	3A: Entospletinib; 3A: High dose daunorubicin;
KMT2A	KMT2A-MLLT3 Fusion	APLPMLRARA	3A: Entospletinib; 3A: High dose daunorubicin;
KMT2A	KMT2A-MLLT3 Fusion	Colorectal Cacner
PDGFRB	PDGFRB-CSF1R Fusion	CMML	1: Imatinib;
PDGFRB	PDGFRB-CSF1R Fusion	Colorectal Cancer	2B: Imatinib;
BRAF	K601E	CMML	3B: Trametinib; 4: PLX8394;
ARAF	S214A	HDCN	3A: Sorafenib;
ARAF	S214A	ECD	3A: Sorafenib;
ARAF	S214A	RDD	3B: Sorafenib;
ARAF	S214A	Colorectal Cancer	3B: Sorafenib;
TP53	K292T	AML	3A: Decitabine; 3A: Entospletinib+Decitabine;
TP53	K292T	APLPMLRARA	3A: Decitabine; 3A: Entospletinib+Decitabine;
TP53	K292T	Colorectal cancer
